U.S., March 3 -- PAMAfrica - a consortium led by Medicines for Malaria Venture (MMV) - will receive US$49mn over the next five years to invest in antimalarials.

The PAMAfrica consortium, aims to bring together global medical companies and academic institutes, to be a part of a not-for-profit product development partnership, to develop new medicines for both severe and uncomplicated malaria.

"Malaria continues needlessly to take 405,000 lives a year and must remain a global and national priority in endemic countries," commented Dr Michael Makanga, Executive Director of EDCTP, "We hope our funding for PAMAfrica will contribute to the development of successful new treatments that will support malaria eradication, while supporting the devel...